MX2018008868A - Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso. - Google Patents

Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.

Info

Publication number
MX2018008868A
MX2018008868A MX2018008868A MX2018008868A MX2018008868A MX 2018008868 A MX2018008868 A MX 2018008868A MX 2018008868 A MX2018008868 A MX 2018008868A MX 2018008868 A MX2018008868 A MX 2018008868A MX 2018008868 A MX2018008868 A MX 2018008868A
Authority
MX
Mexico
Prior art keywords
extended release
abuse deterrent
pharmaceutical compositions
containing pharmaceutical
glucomannan
Prior art date
Application number
MX2018008868A
Other languages
English (en)
Inventor
Han Park Jae
J Herman Clifford
L Gower Brad
Feng Kai
Chung Lai Tsz
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2018008868A publication Critical patent/MX2018008868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Una composición farmacéutica que comprende al menos un ingrediente farmacéuticamente activo (API, por sus siglas en inglés) o una sal farmacéuticamente aceptable de este, un glucomanano, un primer óxido de polialquileno que tiene un peso molecular promedio de no más de 300.000, y un segundo óxido de polialquileno que tiene un peso molecular promedio de al menos 1.000.000 y métodos para elaborarla. La composición farmacéutica proporciona liberación prolongada del API y tiene características disuasivas de abuso.
MX2018008868A 2016-02-08 2017-01-27 Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso. MX2018008868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662292463P 2016-02-08 2016-02-08
PCT/US2017/015235 WO2017139106A1 (en) 2016-02-08 2017-01-27 Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties

Publications (1)

Publication Number Publication Date
MX2018008868A true MX2018008868A (es) 2018-09-21

Family

ID=59497317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008868A MX2018008868A (es) 2016-02-08 2017-01-27 Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.

Country Status (7)

Country Link
US (1) US11065246B2 (es)
EP (1) EP3413893A4 (es)
JP (1) JP2019504072A (es)
AU (1) AU2017216904B2 (es)
CA (1) CA3013321A1 (es)
MX (1) MX2018008868A (es)
WO (1) WO2017139106A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3413893A4 (en) 2016-02-08 2019-08-28 SpecGx LLC PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCOMANNAN WITH EXTENDED RELEASE AND WITH ABUSE DISSUASION PROPERTIES
US20220105041A1 (en) * 2019-01-18 2022-04-07 Merck Patent Gmbh Method for manufacturing a solid administration form and solid administration
JP2023500597A (ja) * 2019-10-29 2023-01-10 アネモリックス，エルエルシー 多孔質グルコマンナンスキャフォールド及びスキャフォールドを製造する方法
CN112315924A (zh) * 2020-11-10 2021-02-05 迪沙药业集团有限公司 一种阿奇霉素组合物及其制备方法
JP7180941B1 (ja) 2021-08-02 2022-11-30 株式会社創研 皮脂分泌抑制剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325046T3 (es) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible por fusion en caliente.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AUPR839001A0 (en) 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
AU2007230730B2 (en) 2006-03-24 2013-03-28 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2393487B1 (en) * 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
CA2853764C (en) 2011-11-22 2017-05-16 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
EP2838516B1 (en) * 2012-04-18 2018-10-17 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
US20130280176A1 (en) * 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate Release Pharmaceutical Compositions with Abuse Deterrent Properties
US9549899B2 (en) * 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014011830A1 (en) * 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CA2791206A1 (en) * 2012-09-28 2014-03-28 Pharmascience Inc. Abuse deterrent pharmaceutical formulation
PL2968182T3 (pl) 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
AU2015284078B2 (en) * 2014-07-03 2020-01-30 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
EP3413893A4 (en) 2016-02-08 2019-08-28 SpecGx LLC PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCOMANNAN WITH EXTENDED RELEASE AND WITH ABUSE DISSUASION PROPERTIES

Also Published As

Publication number Publication date
AU2017216904B2 (en) 2021-11-18
US11065246B2 (en) 2021-07-20
JP2019504072A (ja) 2019-02-14
BR112018014839A2 (pt) 2018-12-18
US20170224826A1 (en) 2017-08-10
EP3413893A1 (en) 2018-12-19
CA3013321A1 (en) 2017-08-17
WO2017139106A1 (en) 2017-08-17
EP3413893A4 (en) 2019-08-28
AU2017216904A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2018008868A (es) Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2020000618A (es) Composicion farmaceutica.
EP3804716A4 (en) PHARMACEUTICAL COMBINATION, COMPOSITION AND COMBINATION PREPARATION WITH A GLUCOKINASE ACTIVATOR AND A SGLT-2 INHIBITOR, METHOD FOR THE PREPARATION AND USE THEREOF
EP3681949A4 (en) FLUORINATED COPOLYMER AND COMPOSITIONS AND ARTICLES USING IT
CN107397757A8 (zh) 润滑剂制剂
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
EP3894398A4 (en) 3,3-DIFLUORALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
EP4003225A4 (en) BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
EP3786167A4 (en) MACROCYCLIC COMPOUND DIARYL, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
EP4041734C0 (en) DERIVATIVES CONTAINING 1,2,3,4-TETRAHYDRONAPHTHALENE UNIT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP3556352A4 (en) COMPOSITION OF AMPHIPHILIC SEQUENCED COPOLYMER WITH IMPROVED MICELLAR STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING IT
AU2017262586A1 (en) Improved drug formulations
IL289932A (en) History of 6,3-diamino-pyridazin-3-yl, pharmaceutical preparations containing them and their use as pro-apoptotic agents
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
EP3539978A4 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT
MX2017016774A (es) Agente terapeutico para la fibrosis.
WO2018085495A3 (en) Dissolvable films and methods of their use
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
WO2018017190A3 (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv